Literature DB >> 25899412

CT differentiation of poorly-differentiated gastric neuroendocrine tumours from well-differentiated neuroendocrine tumours and gastric adenocarcinomas.

Seong Ho Kim1, Se Hyung Kim, Min-A Kim, Cheong-il Shin, Joon Koo Han, Byung Ihn Choi.   

Abstract

PURPOSE: To evaluate the differential CT features of gastric poorly-differentiated neuroendocrine tumours (PD-NETs) from well-differentiated NETs (WD-NETs) and gastric adenocarcinomas (ADCs) and to suggest differential features of hepatic metastases from gastric NETs and ADCs.
MATERIALS AND METHODS: Our study population was comprised of 36 patients with gastric NETs (18 WD-NETs, 18 PD-NETs) and 38 patients with gastric ADCs who served as our control group. Multiple CT features were assessed to identify significant differential CT findings of PD-NETs from WD-NETs and ADCs. In addition, CT features of hepatic metastases including the metastasis-to-liver ratio were analyzed to differentiate metastatic NETs from ADCs.
RESULTS: The presence of metastatic lymph nodes was the sole differentiator of PD-NETs from WD-NETs (P = .001, odds ratio = 56.67), while the presence of intact overlying mucosa with mucosal tenting was the sole significant CT feature differentiating PD-NETs from ADCs (P = .047, odds ratio = 15.3) For hepatic metastases, metastases from NETs were more hyper-attenuated than those from ADCs.
CONCLUSION: The presence of metastatic LNs and intact overlying mucosa with mucosal tenting are useful CT discriminators of PD-NETs from WD-NETs and ADCs, respectively. In addition, a higher metastasis-to-liver ratio may help differentiate hepatic metastases of gastric NETs from those of gastric ADCs with high accuracy. KEY POINTS: • Presence of metastatic LNs is a useful differentiator of PD-NETs from WD-NETs. • Intact overlying mucosa with mucosal tenting suggests PD-NETs more than gastric ADCs. • Metastatic LNs are larger in size and greater in necrotic volume in PD-NETs. • Hepatic metastases from gastric NETs are more hyper-attenuated than those from ADCs.

Entities:  

Mesh:

Year:  2015        PMID: 25899412     DOI: 10.1007/s00330-015-3600-z

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  23 in total

1.  Treatment of type II gastric carcinoid tumors with somatostatin analogues.

Authors:  P Tomassetti; M Migliori; G C Caletti; P Fusaroli; R Corinaldesi; L Gullo
Journal:  N Engl J Med       Date:  2000-08-24       Impact factor: 91.245

2.  Effect of adjusted positioning on gastric distention and fluid distribution during CT gastrography.

Authors:  Se Hyung Kim; Jeong Min Lee; Joon Koo Han; Jae Young Lee; Han Kwang Yang; Hyuk-Joon Lee; Kyung-Sook Shin; Byung Ihn Choi
Journal:  AJR Am J Roentgenol       Date:  2005-11       Impact factor: 3.959

3.  Three-dimensional MDCT for preoperative local staging of gastric cancer using gas and water distention methods: a retrospective cohort study.

Authors:  Hee Sun Park; Jeong Min Lee; Se Hyung Kim; Jae Young Lee; Han-Kwang Yang; Joon Koo Han; Byung Ihn Choi
Journal:  AJR Am J Roentgenol       Date:  2010-12       Impact factor: 3.959

4.  Management of early gastrointestinal neuroendocrine neoplasms.

Authors:  Hans Scherübl; Robert T Jensen; Guillaume Cadiot; Ulrich Stölzel; Günter Klöppel
Journal:  World J Gastrointest Endosc       Date:  2011-07-16

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Radiofrequency ablation treatment of refractory carcinoid hepatic metastases.

Authors:  F J Wessels; S R Schell
Journal:  J Surg Res       Date:  2001-01       Impact factor: 2.192

7.  Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

Authors:  P Ruszniewski; P Rougier; A Roche; P Legmann; A Sibert; S Hochlaf; M Ychou; M Mignon
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

8.  Multimodality treatment for gastric carcinoid tumor with liver metastases.

Authors:  M E Caplin; H J Hodgson; A P Dhillon; R Begent; J Buscombe; R Dick; K Rolles; A K Burroughs
Journal:  Am J Gastroenterol       Date:  1998-10       Impact factor: 10.864

Review 9.  Pathogenesis of ECL cell tumors in humans.

Authors:  C Bordi; T D'Adda; C Azzoni; G Ferraro
Journal:  Yale J Biol Med       Date:  1998 May-Aug

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  13 in total

1.  CT Perfusion evaluation of gastric cancer: correlation with histologic type.

Authors:  Dong Ho Lee; Se Hyung Kim; Ijin Joo; Joon Koo Han
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

2.  Poorly-differentiated colorectal neuroendocrine tumour: CT differentiation from well-differentiated neuroendocrine tumour and poorly-differentiated adenocarcinomas.

Authors:  Ji Hee Kang; Se Hyung Kim; Joon Koo Han
Journal:  Eur Radiol       Date:  2017-02-16       Impact factor: 5.315

Review 3.  Gastric neuroendocrine neoplasms: a primer for radiologists.

Authors:  Molly E Roseland; Isaac R Francis; Kimberly L Shampain; Erica B Stein; Ashish P Wasnik; John D Millet
Journal:  Abdom Radiol (NY)       Date:  2022-04-12

4.  Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade.

Authors:  Yangyang Wang; Bingfeng Huang; Qihan Fu; Jianing Wang; Mao Ye; Manyi Hu; Kai Qu; Kai Liu; Xiao Hu; Shumei Wei; Ke Sun; Wenbo Xiao; Bo Zhang; Haijun Li; Jingsong Li; Qi Zhang; Tingbo Liang
Journal:  Ann Surg Oncol       Date:  2022-07-18       Impact factor: 4.339

5.  Outcome and CT differentiation of gallbladder neuroendocrine tumours from adenocarcinomas.

Authors:  Tae-Hyung Kim; Se Hyung Kim; Kyoung Boon Lee; Joon Koo Han
Journal:  Eur Radiol       Date:  2016-05-25       Impact factor: 5.315

6.  Value of computed tomography evaluation in pathologic classification and prognosis prediction of gastric neuroendocrine tumors.

Authors:  Shida Yan; Tongtong Liu; Ying Li; Yongjian Zhu; Jun Jiang; Liming Jiang; Hong Zhao
Journal:  Ann Transl Med       Date:  2019-10

7.  Computed tomography-based radiomics for prediction of neoadjuvant chemotherapy outcomes in locally advanced gastric cancer: A pilot study.

Authors:  Zhenhui Li; Dafu Zhang; Youguo Dai; Jian Dong; Lin Wu; Yajun Li; Zixuan Cheng; Yingying Ding; Zaiyi Liu
Journal:  Chin J Cancer Res       Date:  2018-08       Impact factor: 5.087

8.  Radiographic characteristics of neuroendocrine liver metastases do not predict clinical outcomes following liver resection.

Authors:  Emily A Armstrong; Eliza W Beal; Manisha Shah; Bhavana Konda; Sherif Abdel-Misih; Aslam Ejaz; Mary E Dillhoff; Timothy M Pawlik; Jordan M Cloyd
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

9.  Utility of CT in differentiating liver metastases of well-differentiated gastroenteropancreatic neuroendocrine neoplasms from poorly-differentiated neuroendocrine neoplasms.

Authors:  Yong Cui; Xiaoting Li; Shunyu Gao; Zhongwu Li; Yanling Li; Ming Lu; Yingshi Sun
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

10.  Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics.

Authors:  Jeong Sub Lee; Se Hyung Kim; Seock-Ah Im; Min A Kim; Joon Koo Han
Journal:  Korean J Radiol       Date:  2017-07-17       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.